Mallinckrodt

Acclaimed Cardiology Expert Dr. Peter Libby To Keynote 19th Annual CMHC, Revolutionize Atherosclerosis Care

Retrieved on: 
Mittwoch, Mai 22, 2024
Diabetes, Patient, Cardiovascular disease, Kidney disease, Risk, Liver disease, CMHC, Valentín Fuster, Treatment, Immunity, Mallinckrodt, MD, Brigham and Women's Hospital, Research, Harvard Medical School, Hospital, Inflammation, BWH

Dr. Peter Libby is a cardiovascular medicine specialist at Brigham and Women's Hospital (BWH) and the Mallinckrodt Professor of Medicine at Harvard Medical School.

Key Points: 
  • Dr. Peter Libby is a cardiovascular medicine specialist at Brigham and Women's Hospital (BWH) and the Mallinckrodt Professor of Medicine at Harvard Medical School.
  • A world-renowned author and lecturer on cardiovascular medicine and atherosclerosis, Dr. Libby has been published extensively in leading medical journals.
  • He led the pivotal Canakinumab Anti-Inflammatory Thrombosis Outcomes Trial (CANTOS), which clinically validated the role of inflammation in atherosclerosis.
  • Dr. Peter Libby's keynote, "Prevention and Treatment of Atherosclerosis," at the 19th Annual CMHC conference will provide an update on his research on inflammation and atherosclerosis.

Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients

Retrieved on: 
Donnerstag, Mai 16, 2024
Patient, ACTE, Doctor of Philosophy, Organization, American Heart Association, Sarcoidosis, Conditional sentence, Coalition, Yale school, Education, Patient education, Compensation, Clinical trial, Yale School of Medicine, Chan Zuckerberg Initiative, Mallinckrodt, Engagement, Associate, African Americans, Committee, Quality of life, FSR, IRB, Pharmaceutical industry

This initiative aims to increase representation of Black and African American patients in clinical trials, thereby improving health outcomes for marginalized communities.

Key Points: 
  • This initiative aims to increase representation of Black and African American patients in clinical trials, thereby improving health outcomes for marginalized communities.
  • Lack of diversity in clinical trials hinders the development of effective treatments that cater to the needs of all populations, especially those most severely impacted.
  • "This coalition will leverage the extensive experience and diverse professional expertise of its leaders to drive forward actionable strategies.
  • By increasing clinical trial participation among Black Americans, we can advance therapies, curtail medical costs, and enhance the quality of life for those affected by chronic illness."

Nucleai Appoints Vikas Ahuja as Vice President of Strategic Partnerships to Enable Diagnostic Deployment and Commercialization at Scale

Retrieved on: 
Donnerstag, Mai 16, 2024
Data Management, Health, Technology, Software, Artificial Intelligence, Pharmaceutical, Biotechnology, Partnership, ChromeOS, Imperial College London, Chemical engineering, University, Ecosystem, MBA, Mallinckrodt, AI, Genetics, Ahuja, Biomarker, International, Therapy, Business development, Knowledge, Multimedia, Management

View the full release here: https://www.businesswire.com/news/home/20240516792275/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240516792275/en/
    Pictured: Vikas Ahuja, Vice President of Strategic Partnerships, Nucleai (Photo: Business Wire)
    "Vikas has a wealth of experience and knowledge in business development across various sectors within the life sciences industry and is a perfect addition to our team,” said Avi Veidman, CEO of Nucleai.
  • Vikas’ proven track record of fostering strategic alliances and driving global growth initiatives speaks volumes about his expertise in building partnerships to scale the deployment of novel diagnostics.
  • "This role presents a tremendous opportunity to leverage my experience in building impactful collaborations across the life sciences sector,” said Ahuja.
  • Ahuja earned his MBA from The Wharton School of the University of Pennsylvania and his MS in Chemical Engineering from Imperial College, London.

Prevent Blindness to Host the 2024 ASPECT Patient Engagement and Advocacy Summit in Washington, D.C.

Retrieved on: 
Dienstag, Mai 7, 2024
Public, Summit, Partner, Risk, Policy, Disability, Advocacy, Kyowa Kirin, Spark Therapeutics, Biotechnology Innovation Organization, Human, BIO, Communication, Public policy, Novartis, Patient, MPH, Patient advocacy, Conditional sentence, Madison Hotel, Visual impairment, CVC, Knowledge, Mallinckrodt, Nursing

CHICAGO, May 7, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health and safety organization, will be hosting the ASPECT Patient Engagement and Advocacy Summit, May 14-16, 2024, at the Madison Hotel in Washington, D.C. The Summit will bring together ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program graduates (eye health patients and their allies), and program sponsors.

Key Points: 
  • Three-day event brings together patients, care partners, and public health champions to advance the goals of the Prevent Blindness ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program
    CHICAGO, May 7, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health and safety organization, will be hosting the ASPECT Patient Engagement and Advocacy Summit, May 14-16, 2024, at the Madison Hotel in Washington, D.C.
  • The Summit will bring together ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program graduates (eye health patients and their allies), and program sponsors.
  • The ASPECT Patient Engagement and Advocacy Summit is generously supported by Sustaining Level Partners Amgen, Genentech, and Novartis.
  • For information on Prevent Blindness advocacy efforts, please visit Advocacy.PreventBlindness.org , or contact Sara Brown, Director of Government Affairs, at [email protected] .

Lineage Announces Changes to Board of Directors

Retrieved on: 
Montag, April 29, 2024
Biotechnology, Health, Stem Cells, Mallinckrodt, Sale, University, General counsel, Economics, Compensated emancipation, Audit committee, PJT Partners, Bachelor of Arts, Therapy, Senior advisor, Asterias, Management

Mr. Kingsley served as Chairman of the Company’s Board of Directors since July 2009, and was a significant contributor in the evolution of the Company into a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs.

Key Points: 
  • Mr. Kingsley served as Chairman of the Company’s Board of Directors since July 2009, and was a significant contributor in the evolution of the Company into a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs.
  • Effective as of April 27, 2024, Michael H. Mulroy, J.D., has been appointed by the Board of Directors to serve as the Chairman of the Board of Directors.
  • “Al was exceptionally committed to Lineage and its shareholders, and brought great innovation, leadership, and dedication to others to his work.
  • He previously served as Chief Executive Officer and a member of the board of directors of Asterias Biotherapeutics, Inc.

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Retrieved on: 
Mittwoch, April 10, 2024
Mallinckrodt, Financial management, University, Information, Treasury, Sharecare, United Therapeutics, Virginia School for Girls, Hereditary angioedema, Acquisition, Accounting, HAE, Therapy, Amphastar Pharmaceuticals, Strategic planning, Management

In this role, he will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and operations.

Key Points: 
  • In this role, he will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and operations.
  • “David expands Pharvaris’ leadership capabilities as we become a late-stage biotech company with an exciting pipeline and strong commercial potential,” said Berndt Modig, Chief Executive Officer of Pharvaris.
  • He will work closely on investor relations and corporate strategy with Morgan Conn, our Chief Business Officer.
  • Over his career, Mr. Nassif has served as the Chief Financial Officer of Histogen, Zogenix, Amphastar Pharmaceuticals, and RealAge.

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Retrieved on: 
Montag, März 25, 2024
IDM, AbbVie, Mallinckrodt, FASN, KPMG, Growth, Biotechnology, Leukemia, Horizon Therapeutics, Patient, G.D. Searle, LLC, SAN, Acquisition, University, Pleasure, IPSC, Therapy, KPMG LLP, Trustee, Champaign–Urbana metropolitan area, Century, Pharmaceutical industry

I also welcome Paul, whose experience in capital markets as well as accounting and finance will be invaluable for Sagimet’s next steps.

Key Points: 
  • I also welcome Paul, whose experience in capital markets as well as accounting and finance will be invaluable for Sagimet’s next steps.
  • “Sagimet is well-positioned for its next stage of growth, with an experienced team and demonstrated clinical results.
  • In 2023, Amgen acquired Horizon for $28 billion, and Mr. Walbert currently serves as a senior advisor to Amgen.
  • I look forward to working with Tim and Paul who I know will add great value to our Board of Directors.”

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

Retrieved on: 
Mittwoch, März 20, 2024
Joint venture, Patient, Sale, Business analyst, CCHN, IP, Marketing, Research, Mallinckrodt, Absorption, European Economic Area, Gross metropolitan product, Webcast, Asset, Alvogen, Denosumab, Neovascularization, Biosimilar, Macular degeneration, Safety, Food, U.S. FDA, Teva Pharmaceuticals, Revenue, Q3, CES, AMD, FDA, ISK, Administration, Adalimumab, Research and development, Pharmaceutical industry

Management will conduct a business update conference all and live webcast on March 21, 2024 at 8:00 am ET (12:00 pm GMT).

Key Points: 
  • Management will conduct a business update conference all and live webcast on March 21, 2024 at 8:00 am ET (12:00 pm GMT).
  • Alvotech announced positive top-line results from a pharmacokinetic (PK) study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab).
  • Alvotech announced positive top-line results from a PK study for AVT03, a biosimilar candidate to Prolia® and Xgeva®, which both contain denosumab.
  • Alvotech will conduct a business update conference call and live webcast on Thursday, March 21, 2024, at 8:00 am ET (12:00 pm GMT).

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

Retrieved on: 
Dienstag, März 12, 2024
Mallinckrodt, Cirrhosis, Patient, Korran, King Edward Medical University, Drug, Galectin, General surgery, Therapy, Cancer, GALT, Nursing care plan, NASH, Poster, Pharmaceutical industry

NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D.

Key Points: 
  • NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D.
  • as Vice President, Clinical Development.
  • Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry.
  • “We are pleased to welcome Khurram to the Galectin team at such a meaningful time of our development program” said Pol F. Boudes, M.D., Chief Medical Officer.

Global Cell and Gene Therapy Markets Report 2024-2028: Focus on Zolgensma, Yescarta, Kymriah, Abecma, Maci, Tecartus, Epicel - ResearchAndMarkets.com

Retrieved on: 
Mittwoch, April 3, 2024
Health, Genetics, Growth, PTC Therapeutics, Prevalence, Gene editing, ESG, CSL Behring, Roche, Etranacogene dezaparvovec, Gene, Gilead Sciences, Cancer, Eladocagene exuparvovec, Therapy, CRISPR, Mallinckrodt, PTC, Probability, BLA, Pharmaceutical industry

The "Global Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering.
  • The Global Cell and Gene Therapy Market is expected to grow at a compound annual growth rate (CAGR) of 26.40% from 2023 through 2028.
  • The scope of this study encompasses an investigation of the cell and gene therapy market.
  • The report analyzes cell and gene therapy market based on therapy type, product, application, and region.